The Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.
The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
Non-Alcoholic Fatty Liver Disease (NAFLD) Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Non-Alcoholic Fatty Liver Disease (NAFLD) Treatment.
-
Non-Alcoholic Fatty Liver Disease key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Non-Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Non-Alcoholic Fatty Liver Disease Therapeutics Landscape
Globally, several key players are actively working to develop potential therapies for the treatment of Non-alcoholic Fatty Liver Disease (NAFLD). The launch of the therapies is expected to transform the treatment dynamics in the coming years.
As per DelveInsight, Non-Alcoholic Fatty Liver Disease (NAFLD) Market size is expected to increase during the forecast owing to the increasing prevalence of the disease. The expected launch of emerging products such as Resmetirom (MGL-3196), MSDC-0602K, Semaglutide, and Ocalive (obeticholic acid or OCA) will also boost the market growth.
Request for Sample Pages @ Non-Alcoholic Fatty Liver Disease (NAFLD) Emerging Therapies and Key Companies
Non-Alcoholic Fatty Liver Disease (NAFLD) Key Companies:
-
Madrigal Pharmaceuticals, Inc.
-
Cirius Therapeutics
-
Novo Nordisk A/S
-
Intercept Pharmaceuticals
And others
Non-Alcoholic Fatty Liver Disease (NAFLD) Therapies covered in the report include:
-
Resmetirom (MGL-3196)
-
MSDC- 0602K
-
Semaglutide
-
Ocalive (obeticholic acid or OCA)
And many more
The pipeline for Non-alcoholic Fatty Liver Disease (NAFLD) brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.
Download Sample Pages @ https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight
Table of Content
1. Report Introduction
2. Non-Alcoholic Fatty Liver Disease
3. Non-Alcoholic Fatty Liver Disease Current Treatment Patterns
4. Non-Alcoholic Fatty Liver Disease – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease Late Stage Products (Phase-III)
7. Non-Alcoholic Fatty Liver Disease Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Alcoholic Fatty Liver Disease Discontinued Products
13. Non-Alcoholic Fatty Liver Disease Product Profiles
14. Non-Alcoholic Fatty Liver Disease Key Companies
15. Non-Alcoholic Fatty Liver Disease Key Products
16. Dormant and Discontinued Products
17. Non-Alcoholic Fatty Liver Disease Unmet Needs
18. Non-Alcoholic Fatty Liver Disease Future Perspectives
19. Non-Alcoholic Fatty Liver Disease Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Visit to get the sample report: https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/